Objective
to evaluate if a regimen of ticagrelor is superior to twice-daily clopidogrel (75 mg BID) in reducing MACE events within the first month after primary PCI
Study
double-blind, randomised, controlled superiority trial
Population
adult patients with STEMI undergoing primary PCI within 24 hours of symptom onset
Endpoints
MACE (death, myocardial infarction, stent thrombosis, stroke, or target lesion revascularisation) at one month
Conclusion
Ticagrelor was not found to be superior to twice-daily clopidogrel in reducing MACE one month following primary PCI, with similar bleeding rates between the groups.
Hakeem et al. J Am Coll Cardiol. 2025 Dec 9.